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Abstract: Obesity is currently an increasing public health problem. The intra-uterine 
environment plays a critical role in foetal development. The objective of this study is to 
investigate the association of obesity with modifications in the metabolic profiles of 
pregnant women, and their new-borns. Based on the PELAGIE cohort (Brittany, France), 
a sample of 321 pregnant women was divided into 3 groups according to their body mass 
index (BMI) (normal, over-weight and obese). Nuclear magnetic resonance-based 
metabolomics analyses were performed on maternal urine and cord-blood samples. 
Partial Least Squares Regression-Discriminant Analysis (PLS-DA), polytomous and 
logistic regressions were used to differentiate the metabolic profiles of the 3 BMI groups 
after adjusting for potential confounders. 
Specific profiles were observed for the overweight and obese women (BMI>25) compared 
to the normal-weight women: they had a decrease in urinary hippurate excretion 
associated with a decrease in phenylalanine and an increase in creatinine. We also showed 
an increase in the urinary excretion of lactate, citrate, acetate, creatine, and lysine only in 
obese women (BMI>30) compared to the normal-weight women. The PLS-DA modelling 
did not reveal any significant difference between the cord-blood metabolic profiles of 
newborns according to maternal BMI – although infants born of obese women had a 
higher birth weight and a lower Apgar score. Our results confirmed the potential link 
between obesity and gut microbiota disruption (changes in urinary acids), as well as 
energy and amino-acid metabolism but did not reveal any disruption among newborns. 
 
Keywords: Metabolomics, Obesity, Biomarkers, System biology. 
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Introduction 
Obesity, associated with type II diabetes or cardiovascular diseases, has reached epidemic 
status. A third of American women of reproductive age are obese (Orsi et al., 2011). Now, 
epidemiological studies have shown increased birth weight in new-borns from obese mothers, 
associated with a higher risk of developing obesity in the future (Muhlhausler et al., 2013; 
Symonds et al., 2013). Epidemiological studies, experimentations on animals and placental 
models have shown the critical role played by the intrauterine environment in foetal 
development, including a direct transmission of obesity or metabolic pathologies (Dong et al., 
2013; Symonds et al., 2013). For example, the male offspring of mice with gestational obesity 
developed excess weight, insulin resistance and hyperleptinemia at adulthood, without any 
post-natal obesogenic influence (Dahlhoff et al., 2014). Furthermore, several human studies 
based on mother-child cohorts have found an association between maternal obesity and 
disrupted childhood metabolism associated with cardiovascular diseases (Godfrey and Barker, 
2000; O’Reilly and Reynolds, 2013; Wen et al., 2011). 
These phenomena, known as “foetal programming” involve different mechanisms (Bouanane 
et al., 2010; Symonds et al., 2013; Zambrano and Nathanielsz, 2013). First of all, several studies 
provide supporting evidence on the involvement of an epigenetic mechanism. In one human 
cohort, modifications in DNA methylation at the leptin and adiponectin genes have been 
observed in placentas exposed to maternal gestational diabetes mellitus (Bouchard et al., 2012, 
2010). In another, global methylation levels in the placenta and umbilical cord-blood was higher 
with obesity (Nomura et al. 2014). 
Secondly, overexpression of certain miRNA in foetal muscle from obese mothers has been 
shown in a model of maternal obesity in ewes, suggesting a decrease in adipogenic markers and 
in inflammatory cytokines (Yan et al., 2013). In rats, the wiring of connections within the 
Hypothalamic Arcuate Nuclei (HAC) - a complex energy and appetite control system - occurs 
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in the first 3 weeks of life coincident with a peak in leptin in the new-born pups’ peripheral 
blood. Pups born of obese mothers have a distorted plasma leptin peak that is longer lasting and 
higher in amplitude  (Kirk et al., 2009). This could be the sign of a perturbation in HAC 
development, resulting in future resistance to leptin feedback and energy balance alterations. 
Hormonal changes in foetuses from obese mothers - such as increased cortisol levels or 
decreased thyroxine (T4) levels - have also been reported as potential mechanisms involved in 
programmed obesity (Guzmán et al., 2006; Magyar et al., 1980; Nuermaimaiti Tuersunjiang, 
2013; Suter et al., 2012). Changes in placenta function have also been observed, with 
inflammation and changes in glucose or amino acid transport rates (Challier et al., 2008; Farley 
et al., 2010; Jones et al., 2009). Maternal reactive oxygen and nitrogen species, which are 
associated with intrauterine oxidative stress, also seem to play a role in obesity programming. 
Indeed, oxidative stress is suspected of being implicated in mitochondrial damage, changes in 
pancreas functions and dysfunctions of the electron transport chain in skeletal muscle (Shelley 
et al., 2009; Simmons et al., 2005). There is also supporting evidence for a link between 
maternal exposure to xenobiotics and chemicals, and higher Body Mass Index (BMI) in 
offspring (Janesick and Blumberg, 2011; Karmaus et al., 2009; Smink et al., 2008). 
Otherwise, some of these mechanisms (epigenetics, corticosteroids, miRNA or maternal 
exposure to chemicals) are investigated for the understanding of the programming of obesity 
for children exposed to famine in utero (Inadera, 2013). Most studies have been undertaken in 
animal models. 
Metabolomics describes the study of the metabolome, which is defined as the collective set of 
metabolites produced or present in a sample of interest, for example blood or other biological 
fluid, tissue lysate or cells. Metabolomics based on spectroscopic techniques, is able to generate 
“fingerprints” or metabolic profiles that can be correlated with phenotypes. The metabolic 
profile constitutes the ultimate step in the cellular response, and is considered the key link 
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between genes and phenotypes (Fiehn, 2002). It has come to be widely used in recent years to 
identify metabolic pathways modified by disease (Vinayavekhin et al., 2010). This technique 
has already proved its capacity to study the physiopathology of obesity in animal and human 
studies (Zhang, Sun, et Wang 2013). When it is non-targeted, variations can be shown in the 
levels of metabolites between different groups of population without a priori.  
Metabolomics have already been used to investigate metabolic differences between pregnant 
and non-gravid women (Lowe and Karban, 2014) as well as to analyse metabolic differences 
between obese and normal weight people (Xie et al., 2012a).  The aim of the present study is to 
investigate the existence of differential urinary metabolic profiles in pregnant women according 
to their obesity status, and to understand whether observed changes are associated with 
modifications in the new-born metabolic profile. Thus, we have used Nuclear Magnetic 
Resonance (NMR)-based metabolomics analysis on urinary and cord-blood samples of 
pregnant women and new-borns from the PELAGIE cohort (Brittany, France). To our 
knowledge, this is the first study to investigate the maternal programming of obesity in a human 
population, using metabolomics. 
 
Material and Methods 
Population, sample collection and obesity groups 
The population was selected from the PELAGIE cohort, which includes 3,421 pregnant women 
in Brittany (France) enrolled during early pregnancy from the general population by 
gynaecologists, between 2002 and 2006. Gynaecologists informed the women of the nature of 
the study and asked them to participate, after providing written consent. This consent was 
accompanied by a letter of information describing the goal of the study, the consortium, data 
collection procedures and follow-up after birth (via questionnaires and medical examinations). 
Explicit mention was made of the right to refuse to participate, and the fact that such a refusal 
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would not have any effect on the woman's relationship with her doctor. Both the INSERM 
(French National Institute of Health and Medical Research) ethics committee and the National 
Commission in charge of Data Protection (CNIL) approved the study procedures (Nu902076; 
31 may 2002).  A detailed description of this cohort is available elsewhere (Chevrier et al., 
2011). At inclusion, during the first trimester of the pregnancy (4th to 15th week), women had 
to complete a self-report questionnaire including information about social and demographic 
characteristics, diet and lifestyle, and data on their height and weight (used to calculate BMI). 
They also had to return a first morning void urine sample that they collected and transferred 
into two vials containing nitric acid to avoid bacterial degradation. No blood collection was 
planned at this step of inclusion because of the absence of hospital appointment. Samples were 
mailed to the study laboratory in a pre-stamped package at ambient temperature, with routine 
delivery taking 1 to 3 days. Upon receipt, the 10 mL samples were frozen and stored at -20°C. 
At birth, medical data on health outcomes were obtained and cord-blood samples were 
collected. After centrifugation, serum samples were analysed by hospital laboratories and stored 
at -20°C. 
Pregnant women were selected from the PELAGIE according to the following criteria: living 
infant at birth (n=3322) and availability of both urinary and cord blood samples for each 
mother-child pair (n=1061). In addition, one year of inclusion (2004) was selected, to avoid 
potential variability due to different storage durations of biological samples. A detailed 
description of this methodology is published elsewhere (Bonvallot et al., 2013). Of the 338 
eligible women, those whose BMI was unavailable or below 18.5 were excluded (n = 15), 
because low body weight can influence metabolic profiles (Norman et al., 2014; Sarlio-
Lähteenkorva et al., 2004). Finally, the population analysed included 323 women, who were 
classified into 3 groups of BMI, according to the World Health Organization (WHO)’s 
definition (WHO Expert Consultation, 2004): the first group comprised women with a BMI of 
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between 18.5 and < 25 (normal weight), the second those with a BMI between 25 and < 30 
(overweight) and the third, those with a BMI of 30 or more (obese). 
Metabolomics analyses 
Urinary sample preparation: After thawing at room temperature and vortexing, 500 μL of urine 
were mixed with 200 μL of phosphate buffer (pH 7.39) prepared in D2O to which was added 
sodium 3-trimethylsilyl-1-[2,2,3,3,-2H4]-propionate (TSP, 1 mM). The phosphate buffer is used 
to minimize variations in chemical shift values in the acquired NMR spectra due to pH 
differences. TSP served as a chemical shift reference and D2O served as a field-frequency lock 
for the NMR spectrometer. Each sample was vortexed and centrifuged for 10 min at 8,000 rpm 
to remove any precipitate. Then, 600 μL aliquots were transferred to standard 5 mm - NMR 
tubes (Norell ST 500, Landisville, NJ) for analysis. 
Serum sample preparation: After thawing at room temperature and vortexing, 200 μL of serum 
were mixed with 500 μL of D2O which served as a field-frequency lock for the NMR 
spectrometer. Each sample was vortexed and centrifuged for 10 min at 8,000 rpm to remove 
any precipitate. Then, 600 μL aliquots were transferred to NMR tubes for analysis. 
Metabolomics analyses: Metabolomics analyses of urine and cord-blood samples were made 
by NMR spectroscopy using a Bruker Avance DRX-600 operating at 600.13 MHz (Bruker 
Biospin, Germany) and equipped with an autosampler and an inverse 1H-13C-15N cryoprobe. 
All NMR spectra were phase- and baseline-corrected manually using Topspin (V2.1, Bruker 
Biospin, Germany). The spectral region containing residual water resonance (δ 5.515-6.600) 
was removed and spectra were digitized to 642 and 751 buckets corresponding to 0.01 ppm 
intervals using the AMIX software package (V3.9.11, Bruker Biospin, Germany). Each 
integrated region was divided by the total spectral intensity in order to normalise values. Spectra 
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acquisition, pre-processing step, and metabolite identification have been described previously 
(Bonvallot et al., 2013). 
Statistical analysis: metabolic profiles according to BMI groups. To investigate the association 
of obesity with specific metabolomic profiles, we used Partial Least Square Discriminant 
Analyses (PLS-DA) and multivariate logistic regression models. Our objective was not to 
strictly build predictive models for obesity but rather to study variations in both mother and 
newborn metabolic profiles according to maternal obesity. 
The PLS-DA approach was chosen because it handles highly collinear and noisy data, such as 
spectral data and it has already been used in epidemiological studies which investigated subtle 
health effects in relation to highly variable spectral data (Waterman et al., 2009). It allows 
identifying among the spectrum the most important variables which discriminate the groups of 
interest, using statistics such as the variable importance on projection (VIP).  
Maternal urine and cord blood spectral data were analysed separately. The original digitized 
NMR spectral data were imported into the R software (version 3.1.1) for multivariate statistical 
analysis. A preliminary principal component analysis (PCA) was implemented to remove 
potential outliers. Data were then Pareto-scaled to reduce relative importance of large values, 
while partially preserving data structure (Worley and Powers, 2013). PLS-DA were applied to 
Pareto-scaled data. In PLS-DA, linear combinations of NMR buckets are constructed to 
maximize covariance between the Y (BMI groups) and (NMR buckets) X matrices. 
Observations are then projected onto planes defined by a few of these linear combinations (also 
interpreted as latent variables). Various PLS-DA models were generated: a 3-level model 
measuring the link between the metabolic profiles and the mothers' BMI in 3 groups (Normal 
vs. Overweight vs. Obese) and four 2-level models measuring the link with BMI in 2 groups 
(Normal vs. others, Obese vs. others, Normal vs. Overweight, Overweight vs. Obese). The 
quality of the 3-level models was assessed by the Q2 and the R2 parameters defined as followed: 
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 𝑄2 = 1 −
𝑃𝑅𝐸𝑆𝑆𝑛
𝑅𝑆𝑆𝑛−1
, where PRESS is the predicted residual sum of squares; RSS, the 
residual sum of squares and n, the number of latent variables (LV) 
 𝑅2 = 1 −
𝑃𝑅𝐸𝑆𝑆
𝑇𝑆𝑆
, where TSS is the total sum of squares 
The quality of the 2-level models was assessed by the Q2, R2 and the area under the ROC curve 
(AUROC) criteria, following a 3-2 double-k-fold cross-validation. This consists of two nested 
cross-validation loops. The modelling procedure, including the cross-validation that determines 
the best number of Latent Variables (LV), using the lower PRESS criteria, forms the inner loop. 
Cross-validation for error estimation takes place in the outer loop. Double cross-validation is 
recommended in PLS-DA analysis (Smit et al., 2007; Szymańska et al., 2012). Here, a limited 
number of folds for cross validation (n= 3 in outer loop and n=2 in inner loop) were chosen to 
keep an adequate number of obese mothers in each fold (n= 6 or 7). A random draw was 
performed to allow equal distribution of Obese and Overweight in each fold. A permutation test 
(1,000 iterations) was conducted for each PLS-DA model to test for validity. Finally, the 
spectral regions (buckets) having VIP above 2 were considered as being significantly associated 
with the maternal BMI status and were used to identify the metabolites of interest. Kruskal 
Wallis tests using crude spectral data were used to confirm the relationships between BMI 
groups and concentrations of metabolites in urine or in serum previously identified. 
 
Adjustment for confounding factors 
As PLS-DA did not allow for adjustment, polytomous and logistic regressions were then used 
to assess the association of urinary metabolic profiles with the BMI group (3 levels) after 
adjustment for women's individual characteristics. For each metabolite previously identified 
from the PLS-DA, the corresponding buckets with VIP > 2 were simultaneously introduced in 
the models. Results from these analyses were reported as a global trend (direction of the 
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association) and an adjusted p value. The literature suggested some major confounding factors. 
Age, educational level, alcohol and tobacco consumption, food habits (fruit and fish 
consumption), proportion of area covered by cereal crops in the municipality of residence 
during pregnancy (reflecting pesticide exposure) and Apgar score (at 5 min, only in the analysis 
of cord-blood) were considered as potential confounders and were retained in the model if the 
likelihood ratio (LR) test was statistically significant for at least one metabolite. Then, a 
backward selection using the LR test was performed to select confounders with an impact in 
term of goodness of fit. Finally, none of the confounders has been kept in the models. 
 
Results 
Preliminary PCA identified 2 outliers among the women (urinary analyses). The first one had 
a high concentration of urinary glucose and was identified as diabetic. The second had no 
specific characteristics compared to the other individuals but a high concentration of hippurate 
was detected in her urinary sample. The preliminary PCA among the new-borns (serum 
analyses) did not identify any outlier. Table I describes the characteristics of the 321 women 
finally included in the analyses. Mean maternal age was 30.3 and most of these women had a 
high educational level (university degree). Tobacco and alcohol consumption was limited 
(28.2% and 15.9%).  
Most of the women were of normal-weight (n=256), 46 were overweight and only 19 were 
considered obese according to the WHO definition. Overweight and obese women had higher 
parity than normal weight women (p=0.03), higher incidence of high blood pressure (p=0.006) 
and higher incidence of occupational exposure to solvents (p=0.047). Infants born of 
overweight or obese women had higher birth weight (p=0.02) and those born from obese 
women had lower Apgar scores at five minutes (p=0.02). 
Urinary analyses of pregnant women 
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Obese mothers were distinguished by the first two latent variables, and overweight mothers to 
a slightly lesser extent. The ideal number of latent variables was one or two, depending on 
validation loop (mean = 1.77 in the Normal vs. Overweight vs. Obese model). Separation of the 
3 levels of BMI was significant according to the Q2 (mean=0.01, p=0.006) and R2 (mean=0.02, 
p=0.003) criteria. The separation between normal-weight women and the rest of the population 
was significant according to the AUROC (mean=0.71, p=0.001), Q2 (mean=0.021, p=0.004) 
and R2 (mean =0.05, p=0.001) criteria, as well as the separation between normal-weight and 
overweight women (AUROC=0.66, p=0.003; Q2=0.02, p=0.001; R2=0, p=0.008). The 
separation between obese and the rest of the population was highly significant according to the 
AUROC (mean =0.76, p=0.001) but not to the Q2 and R2. This can be explained by the small 
number of obese women in the population, leading to a lower performance of the classical 
parameters Q2 and R2 in PLS. The separation between obese and overweight women was not 
significant according to any criterion. The score plot derived from the PLS-DA modelling is 
shown in Figure 1. The parameters resulting from the validation procedures and permutation 
tests are described in Table 2. 
Because hypertension and occupational exposure to solvent could also be associated with an 
increased risk in obesity, these characteristics were studied by PLS-DA modelling on urinary 
metabolic profile. The models did not produce any significant separation (data not shown). 
Next, logistic and polytomous regressions were performed on metabolites having VIP above 2: 
direction of the associations and p-values using Kruskal-Wallis test were presented in Table 3. 
Hippurate and phenylalanine levels were lower in obese and overweight women, whereas 
urinary creatinine was higher. Lactate was higher in obese (though not in overweight) women, 
as were creatine, lysine, citrate and acetate. Two unknown signals (δ = 6.925 and δ = 2.345 ppm) 
appeared modified between the BMI groups. 
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Serum analyses of cord-blood at birth 
The metabolic profiles of the cord-blood samples did not show any visual separation on the first 
latent variables, as shown in Figure 2. The parameters resulting from the validation procedure 
and permutation test are presented in Table 4. These validation procedures did not show any 
significant separation according to the BMI group, irrespective of the tested model. No bucket 
having a VIP above 2 was found significantly associated with BMI status by the Kruskal-Wallis 
test. 
 
Discussion               
Our work shows modification to seven urinary metabolites between obese, overweight, and 
normal-weight pregnant women, including hippurate, phenylalanine, lactate, creatine, lysine, 
citrate and acetate, without any measurable association with specific cord-blood metabolic 
profile at birth. The decrease in urinary hippurate and phenylalanine levels and the increase in 
creatinine levels were observed in both obese and overweight women. Increased urinary lactate, 
creatine, lysine, citrate and acetate levels concerned only the obese women. Hippurate, lactate 
and acetate are organic acids which had already been associated with obesity and type 2 
diabetes, especially in studies investigating the influence of gut microbiota (Calvani et al., 2010; 
Dewulf et al., 2013; Phipps et al., 1998; Respondek et al., 2013; Salek et al., 2007; Waldram et 
al., 2009; Williams et al., 2002). In particular, the urinary excretion of hippurate has been 
associated with gut microbiota having  a role in the metabolism of polyphenolic compounds 
(Lees et al., 2013). In addition, there is evidence to suggest that disruptions in gut flora and their 
relationship with the host are associated with the development of obesity (Gross, 2013). 
Decreases in urinary hippurate have been observed both experimentally and in humans (Calvani 
et al., 2010; Friedrich et al., 2012; Salek et al., 2007).  
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An increase in lactate has already been shown in some studies - in urine, blood and hepatic 
tissue (Rull et al., 2009; Serkova et al., 2006). It has been shown that, like hippurate, lactate is 
linked to gut microflora, in particular to Propionibacterium (Dewulf et al., 2013; Respondek et 
al., 2013). Lactate is also a precursor of gluconeogenesis and an elevation could be a sign of 
hepatic disruptions in glucose and glycogen synthesis (Xie et al., 2012b).   
Lastly, an increase in acetate levels has already been observed in the urine and blood of Zucker 
rat (Serkova et al., 2006; Waldram et al., 2009). Acetate is suspected to be linked with 
microbiome, and in particular with Bifidobacterium - which is already known to have a 
protective effect against obesity (Waldram et al., 2009). 
 
It was also shown than amino-acid metabolism could be modified in the event of obesity (Lees 
et al., 2013). The increased urinary lysine we have observed in this study is consistent with 
experimental studies carried out in rats. Changes in lysine degradation were observed in obese 
Zucker rats compared to lean rats, and are potentially associated with impairment to energy 
metabolism, implying perturbations in insulin resistance (Salek et al., 2007). Nevertheless, 
other studies also showed a decrease in plasmatic lysine levels associated with an increase in 
insulin resistance in mice (Won et al., 2013) and a decrease in lysine levels in the adipose tissue 
of obese people (Hanzu et al., 2013). Moreover, lysine acetylation seems to play a role in some 
obesity-induced cancers (Lee et al., 2013). Finally, we know that protein nutrition can have a 
consequence on lipid metabolism (Gudbrandsen et al., 2008). Similar observations were made 
of phenylalanine; several authors have linked its increase with obesity (Kim et al., 2013; Wang 
et al., 2011; Whitehead et al., 2007). A relationship between obesity and the metabolism of 
branched-chain amino acids was hypothesized (Adams, 2011; Kim et al., 2013). On the other 
hand, Won et al. showed a decrease in urinary phenylalanine concentrations in obese mice (Won 
et al., 2013). Despite this discrepancy regarding modifications observed in lysine and 
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phenylalanine levels, it could be concluded that obesity has an influence on amino acid 
metabolism, as has already been suggested in other works (Zhou et al., 2013).  
Citrate is produced from fatty acids and glucose metabolism and is an intermediate in the citrate 
cycle for energy production. Its regulation involves insulin and glucose. The increased levels 
of citrate we observed are consistent with certain studies in diabetic or obese rats (Kim et al., 
2009; Li et al., 2008; Shearer et al., 2008), suggesting a link with hyperglycaemia and insulin 
resistance, while lowered levels have sometimes been measured (Salek et al., 2007; Schirra et 
al., 2008; Zhao et al., 2010). The increased citrate levels could be associated with the increase 
in acetate and lactate levels, suggesting an up-regulation in the citrate cycle. In addition, 
changes in citrate levels could be associated with renal pathologies. It is possible that an 
increase in the urinary secretion of citrate may be a consequence of a metabolic stress induced 
by hyperglycaemia and/or dyslipidaemia, or a consequence of renal dysfunctions (Salek et al., 
2007).  
Creatinine is a break-down product of creatine metabolism in muscles. Urinary and blood 
increases in creatinine and creatine have been observed in obese rodents (Calvani et al., 2010; 
Duggan et al., 2011; Salek et al., 2007; Schirra et al., 2008; Williams et al., 2005; Zhao et al., 
2010). This phenomenon could be explained by cardiac or skeletal muscle hypertrophy as an 
adaptation to support the increase of body mass induced by obesity (Xie et al., 2012b). Urinary 
secretion of creatinine is also used to measure renal function. An increase could be the 
consequence of renal dysfunctions, linked with obesity (Kim et al., 1969; Proczko et al., 2013). 
In recent years, studies have shown that NMR-based metabolomics on urine samples is able to 
identify obesity biomarkers. To the best of our knowledge, our study is the first to use 
metabolomics trying to investigate the mechanisms governing the transmission of obesity. Our 
inability to observe the effect of obese or overweight mothers on offspring metabolic profile 
must be put into perspective. First, the low number of obese women (n= 19) induces a low 
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statistical power. Obesity measurement by BMI, calculated using physiological parameters 
(weight, height) collected by questionnaire may result in measurement errors, in particular an 
underestimation of obese women's weight, leading to a weak separation of BMI subgroups. 
Lastly, it is possible that certain modifications to metabolic profile are not visible at birth - but 
appear later. 
The NMR technique used does have certain advantages: the analysis is highly quantitative, 
measures are reproducible and required preparation is minimal (Dumas et al., 2006; Smolinska 
et al., 2012). The other commonly-used technique in metabolomics is mass spectrometry 
coupled with chromatographic techniques, the advantage of which is the possibility of detecting 
metabolites in lower concentrations (Werner et al. 2008; Breitling et al. 2006). It would be 
interesting to reproduce this kind of study using mass spectrometry, in order to confirm and 
improve the results of our study. 
 
Concluding remarks 
Metabolomics has potential for the study of obesity and the identification of biomarkers, with 
the possibility of a global measurement of metabolic dysfunctions in a biological matrix. This 
study has shown several modifications to the urinary metabolic profile of obese and overweight 
pregnant women when compared with normal-weight pregnant women, yet without being able 
to show any modification to blood metabolic profile of offspring at birth. Changes observed 
include modifications to amino acid metabolism, citrate cycle, and microbiome-host 
relationships. More studies on large human samples will be necessary to establishing strong 
evidence on metabolic modifications involved in the transmission of obesity. 
 
Acknowledgments including grant information 
Ac
ce
ed
 m
an
usc
rip
t
17 
 
We acknowledge financial support from the EHESP School of Public Health, France. We 
gratefully acknowledge Marie Tremblay-Franco for helpful advice on statistics, and Sven 
Delaye for advice on English translation.  
 
References 
Adams, S.H., 2011. Emerging perspectives on essential amino acid metabolism in obesity 
and the insulin-resistant state. Adv. Nutr. Bethesda Md 2, 445–456. doi:10.3945/an.111.000737 
Bonvallot, N., Tremblay-Franco, M., Chevrier, C., Canlet, C., Warembourg, C., Cravedi, 
J.-P., Cordier, S., 2013. Metabolomics tools for describing complex pesticide exposure in 
pregnant women in Brittany (France). PloS One 8, e64433. doi:10.1371/journal.pone.0064433 
Bouanane, S., Merzouk, H., Benkalfat, N.B., Soulimane, N., Merzouk, S.A., Gresti, J., 
Tessier, C., Narce, M., 2010. Hepatic and very low-density lipoprotein fatty acids in obese 
offspring of overfed dams. Metabolism. 59, 1701–1709. doi:10.1016/j.metabol.2010.04.003 
Bouchard, L., Hivert, M.-F., Guay, S.-P., St-Pierre, J., Perron, P., Brisson, D., 2012. 
Placental adiponectin gene DNA methylation levels are associated with mothers’ blood glucose 
concentration. Diabetes 61, 1272–1280. doi:10.2337/db11-1160 
Bouchard, L., Thibault, S., Guay, S.-P., Santure, M., Monpetit, A., St-Pierre, J., Perron, P., 
Brisson, D., 2010. Leptin gene epigenetic adaptation to impaired glucose metabolism during 
pregnancy. Diabetes Care 33, 2436–2441. doi:10.2337/dc10-1024 
Breitling R., Pitt A.R., Barrett M.P. Precision Mapping of the Metabolome. Trends in 
Biotechnology. 2006;24(12):543-548. 
Calvani, R., Miccheli, A., Capuani, G., Tomassini Miccheli, A., Puccetti, C., Delfini, M., 
Iaconelli, A., Nanni, G., Mingrone, G., 2010. Gut microbiome-derived metabolites characterize 
a peculiar obese urinary metabotype. Int. J. Obes. 2005 34, 1095–1098. doi:10.1038/ijo.2010.44 
Ac
cep
te
 m
an
usc
rip
t
18 
 
Challier, J.C., Basu, S., Bintein, T., Minium, J., Hotmire, K., Catalano, P.M., Hauguel-de 
Mouzon, S., 2008. Obesity in pregnancy stimulates macrophage accumulation and 
inflammation in the placenta. Placenta 29, 274–281. doi:10.1016/j.placenta.2007.12.010 
Chevrier, C., Limon, G., Monfort, C., Rouget, F., Garlantézec, R., Petit, C., Durand, G., 
Cordier, S., 2011. Urinary biomarkers of prenatal atrazine exposure and adverse birth outcomes 
in the PELAGIE birth cohort. Environ. Health Perspect. 119, 1034–1041. 
doi:10.1289/ehp.1002775 
Dahlhoff, M., Pfister, S., Blutke, A., Rozman, J., Klingenspor, M., Deutsch, M.J., Rathkolb, 
B., Fink, B., Gimpfl, M., Hrabě de Angelis, M., Roscher, A.A., Wolf, E., Ensenauer, R., 2014. 
Peri-conceptional obesogenic exposure induces sex-specific programming of disease 
susceptibilities in adult mouse offspring. Biochim. Biophys. Acta 1842, 304–317. 
doi:10.1016/j.bbadis.2013.11.021 
Dewulf, E.M., Cani, P.D., Claus, S.P., Fuentes, S., Puylaert, P.G.B., Neyrinck, A.M., 
Bindels, L.B., de Vos, W.M., Gibson, G.R., Thissen, J.-P., Delzenne, N.M., 2013. Insight into 
the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-
type fructans in obese women. Gut 62, 1112–1121. doi:10.1136/gutjnl-2012-303304 
Dong, M., Zheng, Q., Ford, S.P., Nathanielsz, P.W., Ren, J., 2013. Maternal obesity, 
lipotoxicity and cardiovascular diseases in offspring. J. Mol. Cell. Cardiol. 55, 111–116. 
doi:10.1016/j.yjmcc.2012.08.023 
Duggan, G.E., Hittel, D.S., Hughey, C.C., Weljie, A., Vogel, H.J., Shearer, J., 2011. 
Differentiating short- and long-term effects of diet in the obese mouse using (1) H-nuclear 
magnetic resonance metabolomics. Diabetes Obes. Metab. 13, 859–862. doi:10.1111/j.1463-
1326.2011.01410.x 
Dumas, M.-E., Maibaum, E.C., Teague, C., Ueshima, H., Zhou, B., Lindon, J.C., Nicholson, 
J.K., Stamler, J., Elliott, P., Chan, Q., Holmes, E., 2006. Assessment of analytical 
Ac
cep
ted
 m
an
usc
rip
t
19 
 
reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological 
research: the INTERMAP Study. Anal. Chem. 78, 2199–2208. doi:10.1021/ac0517085 
Farley, D.M., Choi, J., Dudley, D.J., Li, C., Jenkins, S.L., Myatt, L., Nathanielsz, P.W., 
2010. Placental amino acid transport and placental leptin resistance in pregnancies complicated 
by maternal obesity. Placenta 31, 718–724. doi:10.1016/j.placenta.2010.06.006 
Fiehn, O., 2002. Metabolomics--the link between genotypes and phenotypes. Plant Mol. 
Biol. 48, 155–171. 
Friedrich, N., Budde, K., Wolf, T., Jungnickel, A., Grotevendt, A., Dressler, M., Völzke, 
H., Blüher, M., Nauck, M., Lohmann, T., Wallaschofksi, H., 2012. Short-term changes of the 
urine metabolome after bariatric surgery. Omics J. Integr. Biol. 16, 612–620. 
doi:10.1089/omi.2012.0066 
Godfrey, K.M., Barker, D.J., 2000. Fetal nutrition and adult disease. Am. J. Clin. Nutr. 71, 
1344S–52S. 
Gross, M., 2013. Does the gut microbiome hold clues to obesity and diabetes? Curr. Biol. 
CB 23, R359–362. 
Gudbrandsen, O.A., Wergedahl, H., Liaset, B., Espe, M., Mørk, S., Berge, R.K., 2008. 
Dietary single cell protein reduces fatty liver in obese Zucker rats. Br. J. Nutr. 100, 776–785. 
doi:10.1017/S0007114508960906 
Guzmán, C., Cabrera, R., Cárdenas, M., Larrea, F., Nathanielsz, P.W., Zambrano, E., 2006. 
Protein restriction during fetal and neonatal development in the rat alters reproductive function 
and accelerates reproductive ageing in female progeny. J. Physiol. 572, 97–108. 
doi:10.1113/jphysiol.2005.103903 
Hanzu, F.A., Vinaixa, M., Papageorgiou, A., Párrizas, M., Correig, X., Delgado, S., 
Carmona, F., Samino, S., Vidal, J., Gomis, R., 2013. Obesity rather than regional fat depots 
Ac
c p
ted
 m
an
usc
rip
t
20 
 
marks the metabolomic pattern of adipose tissue: An untargeted metabolomic approach. Obes. 
Silver Spring Md. doi:10.1002/oby.20541 
Inadera, H., 2013. Developmental origins of obesity and type 2 diabetes: molecular aspects 
and role of chemicals. Environ. Health Prev. Med. 18, 185–197. doi:10.1007/s12199-013-0328-
8 
Janesick, A., Blumberg, B., 2011. Endocrine disrupting chemicals and the developmental 
programming of adipogenesis and obesity. Birth Defects Res. Part C Embryo Today Rev. 93, 
34–50. doi:10.1002/bdrc.20197 
Jones, H.N., Woollett, L.A., Barbour, N., Prasad, P.D., Powell, T.L., Jansson, T., 2009. 
High-fat diet before and during pregnancy causes marked up-regulation of placental nutrient 
transport and fetal overgrowth in C57/BL6 mice. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 
23, 271–278. doi:10.1096/fj.08-116889 
Karmaus, W., Osuch, J.R., Eneli, I., Mudd, L.M., Zhang, J., Mikucki, D., Haan, P., Davis, 
S., 2009. Maternal levels of dichlorodiphenyl-dichloroethylene (DDE) may increase weight and 
body mass index in adult female offspring. Occup. Environ. Med. 66, 143–149. 
doi:10.1136/oem.2008.041921 
Kim, K.E., Onesti, G., Ramirez, O., Brest, A.N., Swartz, C., 1969. Creatinine clearance in 
renal disease. A reappraisal. Br. Med. J. 4, 11–14. 
Kim, M.J., Yang, H.J., Kim, J.H., Ahn, C.-W., Lee, J.H., Kim, K.S., Kwon, D.Y., 2013. 
Obesity-related metabolomic analysis of human subjects in black soybean peptide intervention 
study by ultraperformance liquid chromatography and quadrupole-time-of-flight mass 
spectrometry. J. Obes. 2013, 874981. doi:10.1155/2013/874981 
Kim, S.-H., Yang, S.-O., Kim, H.-S., Kim, Y., Park, T., Choi, H.-K., 2009. 1H-nuclear 
magnetic resonance spectroscopy-based metabolic assessment in a rat model of obesity induced 
by a high-fat diet. Anal. Bioanal. Chem. 395, 1117–1124. doi:10.1007/s00216-009-3054-8 
Ac
cep
ted
 m
nu
scr
ipt
21 
 
Kirk, S.L., Samuelsson, A.-M., Argenton, M., Dhonye, H., Kalamatianos, T., Poston, L., 
Taylor, P.D., Coen, C.W., 2009. Maternal obesity induced by diet in rats permanently 
influences central processes regulating food intake in offspring. PloS One 4, e5870. 
doi:10.1371/journal.pone.0005870 
Lee, J.V., Shah, S.A., Wellen, K.E., 2013. Obesity, cancer, and acetyl-CoA metabolism. 
Drug Discov. Today Dis. Mech. 10, e55–e61. doi:10.1016/j.ddmec.2013.03.005 
Lees, H.J., Swann, J.R., Wilson, I.D., Nicholson, J.K., Holmes, E., 2013. Hippurate: the 
natural history of a mammalian-microbial cometabolite. J. Proteome Res. 12, 1527–1546. 
doi:10.1021/pr300900b 
Li, H., Xie, Z., Lin, J., Song, H., Wang, Q., Wang, K., Su, M., Qiu, Y., Zhao, T., Song, K., 
Wang, X., Zhou, M., Liu, P., Zhao, G., Zhang, Q., Jia, W., 2008. Transcriptomic and 
metabonomic profiling of obesity-prone and obesity-resistant rats under high fat diet. J. 
Proteome Res. 7, 4775–4783. doi:10.1021/pr800352k 
Lowe, W.L., Karban, J., 2014. Genetics, genomics and metabolomics: new insights into 
maternal metabolism during pregnancy. Diabet. Med. J. Br. Diabet. Assoc. 31, 254–262. 
doi:10.1111/dme.12352 
Magyar, D.M., Fridshal, D., Elsner, C.W., Glatz, T., Eliot, J., Klein, A.H., Lowe, K.C., 
Buster, J.E., Nathanielsz, P.W., 1980. Time-trend analysis of plasma cortisol concentrations in 
the fetal sheep in relation to parturition. Endocrinology 107, 155–159. doi:10.1210/endo-107-
1-155 
Muhlhausler, B.S., Gugusheff, J.R., Ong, Z.Y., Vithayathil, M.A., 2013. Nutritional 
approaches to breaking the intergenerational cycle of obesity. Can. J. Physiol. Pharmacol. 91, 
421–428. doi:10.1139/cjpp-2012-0353 
Norman, J.D., Ferguson, M.M., Danzmann, R.G., 2014. Transcriptomics of salinity 
tolerance capacity in Arctic charr (Salvelinus alpinus): a comparison of gene expression profiles 
Ac
cep
ted
 
a
usc
rip
t
22 
 
between divergent QTL genotypes. Physiol. Genomics 46, 123–137. 
doi:10.1152/physiolgenomics.00105.2013 
Nuermaimaiti Tuersunjiang, J.F.O., 2013. Diet reduction in obese ewes from early gestation 
prevents glucose-insulin dysregulation and returns fetal adiposity and organ development to 
control levels. Am. J. Physiol. Endocrinol. Metab. doi:10.1152/ajpendo.00117.2013 
O’Reilly, J.R., Reynolds, R.M., 2013. The risk of maternal obesity to the long-term health 
of the offspring. Clin. Endocrinol. (Oxf.) 78, 9–16. doi:10.1111/cen.12055 
Orsi, C.M., Hale, D.E., Lynch, J.L., 2011. Pediatric obesity epidemiology. Curr. Opin. 
Endocrinol. Diabetes Obes. 18, 14–22. doi:10.1097/MED.0b013e3283423de1 
Phipps, A.N., Stewart, J., Wright, B., Wilson, I.D., 1998. Effect of diet on the urinary 
excretion of hippuric acid and other dietary-derived aromatics in rat. A complex interaction 
between diet, gut microflora and substrate specificity. Xenobiotica Fate Foreign Compd. Biol. 
Syst. 28, 527–537. doi:10.1080/004982598239443 
Proczko, M., Kaska, Ł., Kobiela, J., Stefaniak, T., Zadrożny, D., Śledziński, Z., 2013. 
Bariatric surgery in morbidly obese patients with chronic renal failure, prepared for kidney 
transplantation--case reports. Pol. Przegl. Chir. 85, 407–411. doi:10.2478/pjs-2013-0062 
Respondek, F., Gerard, P., Bossis, M., Boschat, L., Bruneau, A., Rabot, S., Wagner, A., 
Martin, J.-C., 2013. Short-chain fructo-oligosaccharides modulate intestinal microbiota and 
metabolic parameters of humanized gnotobiotic diet induced obesity mice. PloS One 8, e71026. 
doi:10.1371/journal.pone.0071026 
Rull, A., Vinaixa, M., Angel Rodríguez, M., Beltrán, R., Brezmes, J., Cañellas, N., Correig, 
X., Joven, J., 2009. Metabolic phenotyping of genetically modified mice: An NMR 
metabonomic approach. Biochimie 91, 1053–1057. doi:10.1016/j.biochi.2009.04.019 
Salek, R.M., Maguire, M.L., Bentley, E., Rubtsov, D.V., Hough, T., Cheeseman, M., Nunez, 
D., Sweatman, B.C., Haselden, J.N., Cox, R.D., Connor, S.C., Griffin, J.L., 2007. A 
Ac
cep
ted
 m
an
usc
rip
t
23 
 
metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. 
Physiol. Genomics 29, 99–108. doi:10.1152/physiolgenomics.00194.2006 
Sarlio-Lähteenkorva, S., Silventoinen, K., Jousilahti, P., Hu, G., Tuomilehto, J., 2004. The 
association between thinness and socio-economic disadvantage, health indicators, and adverse 
health behaviour: a study of 28 000 Finnish men and women. Int. J. Obes. Relat. Metab. Disord. 
J. Int. Assoc. Study Obes. 28, 568–573. doi:10.1038/sj.ijo.0802596 
Schirra, H.J., Anderson, C.G., Wilson, W.J., Kerr, L., Craik, D.J., Waters, M.J., Lichanska, 
A.M., 2008. Altered metabolism of growth hormone receptor mutant mice: a combined NMR 
metabonomics and microarray study. PloS One 3, e2764. doi:10.1371/journal.pone.0002764 
Serkova, N.J., Jackman, M., Brown, J.L., Liu, T., Hirose, R., Roberts, J.P., Maher, J.J., 
Niemann, C.U., 2006. Metabolic profiling of livers and blood from obese Zucker rats. J. 
Hepatol. 44, 956–962. doi:10.1016/j.jhep.2005.07.009 
Shearer, J., Duggan, G., Weljie, A., Hittel, D.S., Wasserman, D.H., Vogel, H.J., 2008. 
Metabolomic profiling of dietary-induced insulin resistance in the high fat-fed C57BL/6J 
mouse. Diabetes Obes. Metab. 10, 950–958. doi:10.1111/j.1463-1326.2007.00837.x 
Shelley, P., Martin-Gronert, M.S., Rowlerson, A., Poston, L., Heales, S.J.R., Hargreaves, 
I.P., McConnell, J.M., Ozanne, S.E., Fernandez-Twinn, D.S., 2009. Altered skeletal muscle 
insulin signaling and mitochondrial complex II-III linked activity in adult offspring of obese 
mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R675–681. 
doi:10.1152/ajpregu.00146.2009 
Simmons, R.A., Suponitsky-Kroyter, I., Selak, M.A., 2005. Progressive accumulation of 
mitochondrial DNA mutations and decline in mitochondrial function lead to beta-cell failure. 
J. Biol. Chem. 280, 28785–28791. doi:10.1074/jbc.M505695200 
Smink, A., Ribas-Fito, N., Garcia, R., Torrent, M., Mendez, M.A., Grimalt, J.O., Sunyer, J., 
2008. Exposure to hexachlorobenzene during pregnancy increases the risk of overweight in 
Ac
cep
ted
 m
nu
scr
ipt
24 
 
children aged 6 years. Acta Paediatr. Oslo Nor. 1992 97, 1465–1469. doi:10.1111/j.1651-
2227.2008.00937.x 
Smit, S., van Breemen, M.J., Hoefsloot, H.C.J., Smilde, A.K., Aerts, J.M.F.G., de Koster, 
C.G., 2007. Assessing the statistical validity of proteomics based biomarkers. Anal. Chim. Acta 
592, 210–217. doi:10.1016/j.aca.2007.04.043 
Smolinska, A., Blanchet, L., Buydens, L.M.C., Wijmenga, S.S., 2012. NMR and pattern 
recognition methods in metabolomics: from data acquisition to biomarker discovery: a review. 
Anal. Chim. Acta 750, 82–97. doi:10.1016/j.aca.2012.05.049 
Suter, M.A., Sangi-Haghpeykar, H., Showalter, L., Shope, C., Hu, M., Brown, K., Williams, 
S., Harris, R.A., Grove, K.L., Lane, R.H., Aagaard, K.M., 2012. Maternal high-fat diet 
modulates the fetal thyroid axis and thyroid gene expression in a nonhuman primate model. 
Mol. Endocrinol. Baltim. Md 26, 2071–2080. doi:10.1210/me.2012-1214 
Symonds, M.E., Mendez, M.A., Meltzer, H.M., Koletzko, B., Godfrey, K., Forsyth, S., van 
der Beek, E.M., 2013. Early life nutritional programming of obesity: mother-child cohort 
studies. Ann. Nutr. Metab. 62, 137–145. doi:10.1159/000345598 
Szymańska, E., Saccenti, E., Smilde, A.K., Westerhuis, J.A., 2012. Double-check: 
validation of diagnostic statistics for PLS-DA models in metabolomics studies. Metabolomics 
Off. J. Metabolomic Soc. 8, 3–16. doi:10.1007/s11306-011-0330-3 
Vinayavekhin, N., Homan, E.A., Saghatelian, A., 2010. Exploring disease through 
metabolomics. ACS Chem. Biol. 5, 91–103. doi:10.1021/cb900271r 
Waldram, A., Holmes, E., Wang, Y., Rantalainen, M., Wilson, I.D., Tuohy, K.M., 
McCartney, A.L., Gibson, G.R., Nicholson, J.K., 2009. Top-down systems biology modeling 
of host metabotype-microbiome associations in obese rodents. J. Proteome Res. 8, 2361–2375. 
doi:10.1021/pr8009885 
Ac
cep
te
 m
an
usc
rip
t
25 
 
Wang, C., Feng, R., Sun, D., Li, Y., Bi, X., Sun, C., 2011. Metabolic profiling of urine in 
young obese men using ultra performance liquid chromatography and Q-TOF mass 
spectrometry (UPLC/Q-TOF MS). J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 879, 
2871–2876. doi:10.1016/j.jchromb.2011.08.014 
Waterman, D.S., Bonner, F.W., Lindon, J.C. 2009. Review: Spectroscopic and statistical 
methods in metabonomics. Bioanalysis,1(9):1559-1578 , doi:10.4155/bio.09.143  
Wen, X., Triche, E.W., Hogan, J.W., Shenassa, E.D., Buka, S.L., 2011. Prenatal factors for 
childhood blood pressure mediated by intrauterine and/or childhood growth? Pediatrics 127, 
e713–721. doi:10.1542/peds.2010-2000. 
Werner E., Heilier J-F.,  Ducruix C., Ezan E., Junot C., Tabet J-C. Mass Spectrometry for 
the Identification of the Discriminating Signals from Metabolomics: Current Status and Future 
Trends. Journal of Chromatography B. 2008;871(2):143-163. 
Whitehead, T.L., Holley, A.W., Korourian, S., Shaaf, S., Kieber-Emmons, T., Hakkak, R., 
2007. (1)H nuclear magnetic resonance metabolomic analysis of mammary tumors from lean 
and obese Zucker rats exposed to 7,12-dimethylbenz[a]anthracene. Int. J. Mol. Med. 20, 573–
580. 
WHO Expert Consultation, 2004. Appropriate body-mass index for Asian populations and 
its implications for policy and intervention strategies. Lancet 363, 157–163. 
doi:10.1016/S0140-6736(03)15268-3 
Williams, R.E., Eyton-Jones, H.W., Farnworth, M.J., Gallagher, R., Provan, W.M., 2002. 
Effect of intestinal microflora on the urinary metabolic profile of rats: a (1)H-nuclear magnetic 
resonance spectroscopy study. Xenobiotica Fate Foreign Compd. Biol. Syst. 32, 783–794. 
doi:10.1080/00498250210143047 
Williams, R.E., Lenz, E.M., Evans, J.A., Wilson, I.D., Granger, J.H., Plumb, R.S., Stumpf, 
C.L., 2005. A combined (1)H NMR and HPLC-MS-based metabonomic study of urine from 
Ac
ce
ted
 
an
usc
r p
t
26 
 
obese (fa/fa) Zucker and normal Wistar-derived rats. J. Pharm. Biomed. Anal. 38, 465–471. 
doi:10.1016/j.jpba.2005.01.013 
Won, E.-Y., Yoon, M.-K., Kim, S.-W., Jung, Y., Bae, H.-W., Lee, D., Park, S.G., Lee, C.-
H., Hwang, G.-S., Chi, S.-W., 2013. Gender-specific metabolomic profiling of obesity in leptin-
deficient ob/ob mice by 1H NMR spectroscopy. PloS One 8, e75998. 
doi:10.1371/journal.pone.0075998 
Worley, B., Powers, R., 2013. Multivariate Analysis in Metabolomics. Curr. Metabolomics 
1, 92–107. doi:10.2174/2213235X11301010092 
Xie, B., Waters, M.J., Schirra, H.J., 2012a. Investigating potential mechanisms of obesity 
by metabolomics. J. Biomed. Biotechnol. 2012, 805683. doi:10.1155/2012/805683 
Xie, B., Waters, M.J., Schirra, H.J., 2012b. Investigating potential mechanisms of obesity 
by metabolomics. J. Biomed. Biotechnol. 2012, 805683. doi:10.1155/2012/805683 
Yan, X., Huang, Y., Zhao, J.-X., Rogers, C.J., Zhu, M.-J., Ford, S.P., Nathanielsz, P.W., 
Du, M., 2013. Maternal obesity downregulates microRNA let-7g expression, a possible 
mechanism for enhanced adipogenesis during ovine fetal skeletal muscle development. Int. J. 
Obes. 2005 37, 568–575. doi:10.1038/ijo.2012.69 
Zambrano, E., Nathanielsz, P.W., 2013. Mechanisms by which maternal obesity programs 
offspring for obesity: evidence from animal studies. Nutr. Rev. 71 Suppl 1, S42–54. 
doi:10.1111/nure.12068 
Zhang, A., Sun, H., Wang, X., 2013. Power of metabolomics in biomarker discovery and 
mining mechanisms of obesity. Obes. Rev. Off. J. Int. Assoc. Study Obes. 14, 344–349. 
doi:10.1111/obr.12011 
Zhao, L.-C., Zhang, X.-D., Liao, S.-X., Gao, H.-C., Wang, H.-Y., Lin, D.-H., 2010. A 
metabonomic comparison of urinary changes in Zucker and GK rats. J. Biomed. Biotechnol. 
2010, 431894. doi:10.1155/2010/431894 
Ac
cep
ted
 m
an
usc
rip
t
27 
 
Zhou, Y., Qiu, L., Xiao, Q., Wang, Y., Meng, X., Xu, R., Wang, S., Na, R., 2013. Obesity 
and diabetes related plasma amino acid alterations. Clin. Biochem. 46, 1447–1452. 
doi:10.1016/j.clinbiochem.2013.05.045 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ac
cep
ted
 m
an
usc
rip
t
28 
 
 
 
Figure 1: PLS-DA score plot from the 1H NMR urinary metabolic profile from 321 pregnant 
women. The score plot is the projection of observations onto the first two latent variables. The 
PLS-DA model was run on Pareto-scaled data (N=321, R2 =0.02, Q2=0.01). Three groups of 
Body Mass Index (BMI). Green triangles: normal weight women, blue circles: overweight 
women; red squares: obese women.   
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Figure 2: PLS-DA score plot from the 1H NMR cord-blood metabolic profile from 321 
individuals. The score plot is the projection of observations onto the first two latent variables. 
The PLS-DA model was run on Pareto-scaled data, (N=324, R2 =-0.04, Q2=-0.07). Three 
groups of Body Mass Index (BMI). Green triangles: normal weight women, blue circles: 
overweight women; red squares: obese women.  
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Table 1: Characteristics of the 321 pregnant women enrolled in the metabolomics analysis 
according to their Body Mass Index (BMI). Three groups were identified according to the WHO 
definition: Normal-weight women (18.5<BMI<25), overweight women (25<BMI<30) and 
obese women (BMI≥30). 
Characteristics 
General 
population 
(n=321) 
Normal-weight 
women (n=256) 
Overweight 
women 
(n=46) 
Obese 
women 
(n=19) 
p value1 
Maternal characteristics          
BMI (mean ± SD) 22.96 +/- 3.85 21.36 +/- 1.64 27.35 +/- 1.47 33.89 +/- 2.96   
Maternal weight after  
pregnancy, in kg (mean ± SD) 
74.67 +/- 11.16 71.13 +/- 7.94 83.13 +/- 5.95 
100.67 +/- 
13.05 
  
Parity = 1 (N,%) 134 (41.88) 116 (45.49) 13 (28.26) 5 (26.32) 0.03 
Age (mean ± SD) 30.27 +/- 4.22 30.2 +/- 4.21 30.77 +/- 4.55 29.92 +/- 3.61 0.78 
Higher education2 (N,%) 194 (60.62) 161 (63.14) 23 (50) 10 (52.63) 0.19 
High blood pressure (N,%) 12 (3.75) 6 (2.35) 3 (6.52) 3 (15.79) 0.01 
Smoking in early pregnancy 
(N,%) 
90 (28.21) 71 (27.95) 15 (32.61) 4 (21.05) 0.68 
Regular or occasional  
alcohol consumption   (N,%) 
51 (15.94) 46 (17.97) 4 (8.89) 1 (5.26) 0.18 
Regular or occasional 
occupational  
exposure to solvents (N,%) 
138 (50.92) 103 (47.25) 25 (67.57) 10 (62.5) 0.05 
New-born characteristics           
Gestational age at birth in 
weeks  
(mean ± SD) 
39.62 +/- 1.14 39.59 +/- 1.15 39.59 +/- 1.13 40.11 +/- 1.05 0.16 
Male children (N,%) 157 (48.91) 125 (48.83) 23 (50) 9 (47.37) 1 
Birth weight, in g (mean ± SD) 
3494.22 +/- 
393.13 
3464.2 +/- 368.88 
3598.48 +/- 
493.54 
3646.32 +/- 
382.03 
0.06 
Birth height, in cm (mean ± SD) 50.11 +/- 1.79 50.06 +/- 1.73 50.32 +/- 2.2 50.21 +/- 1.36 0.79 
Birth head circumference in cm  
(mean ± SD) 
34.86 +/- 1.32 34.82 +/- 1.31 35.01 +/- 1.44 35.03 +/- 1.12 0.52 
Apgar score  at 5 min (mean ± 
SD) 
9.9 +/- 0.43 9.91 +/- 0.4 9.93 +/- 0.25 9.63 +/- 0.9 0.21 
1 Kruskal-Wallis test for continuous characteristics, chi-squared test for categorical characteristics. 
2 
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Table 2: Validation of the PLS-DA regression models based on maternal urinary metabolic 
profiles in early pregnancy. Models were validated by a 3-2 double cross validation procedure. 
Inner loops were used to define the best number of Latent Variables (LV), using the lower 
PRESS criteria, while parameters were estimated in outer loops. P values were calculated using 
permutation tests (1000 iterations). 
Model 
Best number 
of LV (mean 
+/- SD) 
Parameter Mean +/- SD p value 
Normal vs. Overweight vs. Obese 1.77 +/- 0.76 
Q2 0.01 +/- 0.08 0.006 
R2 0.02 +/- 0.03 0.003 
Normal vs. others 1.33 +/- 0.52 
AUROC 0.71 +/- 0.02 0.001 
Q2 0.02 +/- 0.12 0.004 
R2 0.05 +/- 0.04 0.001 
Obese vs. others 1.77 +/- 0.83 
AUROC 0.76 +/- 0.05 0.001 
Q2 -0.11 +/- 0.11 0.460 
R2 -0.04 +/- 0.03 0.070 
Normal vs. Overweight 1.03 +/- 0.05 
AUROC 0.66 +/- 0.03 0.003 
Q2 0.02 +/- 0.04 0.001 
R2 0 +/- 0.03 0.008 
Overweight vs. obese 1.85 +/- 0.56 
AUROC 0.53 +/- 0.06 0.370 
Q2 -0.69 +/- 1.14 0.540 
R2 -0.19 +/- 0.13 0.160 
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Table 3: Metabolites linked with separation of the BMI groups in the urine of pregnant women, 
direction of the association and p value.  
   Obese Overweight 
 
δ 1H (ppm) 
metabolite 
(VIP > 2) 
BMI class Trend p Trend p 
global 
p 
7.56-7.53, 7.97-
7.96, 7.84-7.82, 
7.64-7.62, 
7.56-7.53 
Hippurate 
versus Normal ↘ <10-3 ↘ 0.002 
<10-3 
Versus Normal + 
Overweight 
↘ <10-3 - - 
versus Overweight ↘ 0.14 nd nd 
7.42-7.41, 7.36, 
3.99-3,98 
Phenylalanine 
versus Normal ↘ <10-3 ↘ 0.04 
<10-3 
versus Normal + 
Overweight 
↘ <10-3 nd nd 
versus Overweight ↘ 0.006 nd nd 
4.12, 1.34-1.32 Lactate 
versus Normal ↗ <10-3 ↗ 0.21 
<10-3 
versus Normal + 
Overweight 
↗ <10-3 nd nd 
versus Overweight ↗ 0.003 nd nd 
4.06, 3.05 Creatinine 
versus Normal ↗ 0.02 ↗ 0.002 
<10-3 
versus Normal + 
Overweight 
↗ 0.05 nd nd 
versus Overweight = 0.88 nd nd 
3.955, 3.045 Creatine 
versus Normal ↗ 0.03 = 0.74 
0.15 
versus Normal + 
Overweight 
↗ 0.04 nd nd 
versus Overweight ↗ 0.52 nd nd 
3.015 Lysine 
versus Normal ↗ 0.005 = 0.96 
0.06 
versus Normal + 
Overweight 
↗ 0.004 nd nd 
versus Overweight ↗ 0.009 nd nd 
2.69, 2.67, 2.65-
2.64, 2.56-2.52 
Citrate 
versus Normal ↗ <10-3 = 0.84 
0.01 
versus Normal + 
Overweight 
↗ <10-3 nd nd 
versus Overweight ↗ 0.01 nd nd 
1.925 
Acetate 
versus Normal ↗ 0.06 ↗ 0.17 
0.03 
versus Normal + 
Overweight 
↗ 0.09 nd nd 
versus Overweight = 0.43 nd nd 
p value are the result of a likelihood ratio test in logistic regression modelling or in ordered polytomous 
regression Normal < Overweight < Obesity (global p value). To ensure the normality of continuous 
variables, logarithms of hippurate, phenylalanine, lactate, creatinine and creatine were used. Acetate has 
been used as a categorical variable, with a cut-off at the median. VIP: Variable Importance in the 
Projection. nd: non determined 
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Table 4: Validation of the PLS-DA regression models based on cord-blood metabolic profiles 
at birth. Models were validated by a 3-2 double cross validation procedure. Inner loops used to 
define the best number of Latent Variables (LV), using the lower PRESS criteria, while the 
parameters were estimated in the outer loops. P values were calculated using permutation test 
(1000 iterations). 
Model 
Best number of 
LV (mean +/- 
SD) 
Parameter Mean +/- SD p value 
Normal vs. Overweight vs Obese 1.6 +/- 1.37 
Q2 -0.07 +/- 0.06 0.594 
R2 -0.04 +/- 0.03 0.474 
Normal vs. others 1.13 +/- 0.23 
AUROC 0.53 +/- 0.05 0.339 
Q2 -0.06 +/- 0.03 0.513 
R2 -0.04 +/- 0.03 0.314 
Obese vs. others 1.08 +/- 0.14 
AUROC 0.45 +/- 0.04 0.711 
Q2 -0.06 +/- 0.02 0.530 
R2 -0.06 +/- 0.02 0.530 
Normal vs. Overweight 1.55 +/- 0.77 
AUROC 0.53 +/- 0.04 0.322 
Q2 -0.12 +/- 0.05 0.845 
R2 -0.08 +/- 0.03 0.653 
Overweight vs. Obese 1.37 +/- 0.48 
AUROC 0.39 +/- 0.06 0.830 
Q2 -0.45 +/- 0.14 0.720 
R2 -0.37 +/- 0.08 0.640 
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